{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Accelerated+Phase+MPN",
    "query": {
      "condition": "Accelerated Phase MPN"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:44:28.178Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02076191",
      "title": "Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2014-02",
      "completion_date": "2018-07-20",
      "has_results": false,
      "last_update_posted_date": "2019-02-28",
      "last_synced_at": "2026-05-22T06:44:28.178Z",
      "location_count": 8,
      "location_summary": "St Louis, Missouri • Buffalo, New York • New York, New York + 3 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076191"
    },
    {
      "nct_id": "NCT04996875",
      "title": "(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Systemic Mastocytosis (AdvSM)",
        "SM With an Associated Hematologic Neoplasm (SM-AHN)",
        "Mast Cell Leukemia (MCL)",
        "Aggressive Systemic Mastocytosis (ASM)"
      ],
      "interventions": [
        {
          "name": "bezuclastinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cogent Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2021-11-09",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-22T06:44:28.178Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04996875"
    },
    {
      "nct_id": "NCT07362225",
      "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycythemia Vera",
        "ET (Essential Thrombocythemia)",
        "Polycythemia Vera (PV)",
        "Essential Thrombocythemia (ET)",
        "Primary Myelofibrosis (MF)",
        "Primary Myelofibrosis (PMF)",
        "Myelofibrosis",
        "Myelofibrosis (MF)",
        "Myelofibrosis, Primary",
        "Myelofibrosis, Post ET",
        "Myelofibrosis, Post PV",
        "Myelofibrosis (PMF)",
        "Myelofibrosis，MF",
        "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis",
        "Myelofibrosis Due to and Following Polycythemia Vera",
        "Myelofibrosis Transformation in Essential Thrombocythemia",
        "Myelofibrosis With High Molecular Risk Mutations",
        "MF",
        "Secondary Myelofibrosis",
        "Secondary Myelofibrosis in Myeloproliferative Disease",
        "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)",
        "Post-Polycythemia Vera Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis (PPV-MF)",
        "Post-polycythemia Vera Myelofibrosis (Post-PV MF)",
        "Post-polycythemia Vera Myelofibrosis(Post-PV MF)",
        "Post-PV MF",
        "Post-Essential Thrombocythemia Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis (PET-MF)",
        "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)",
        "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",
        "Post-ET MF",
        "Pre-fibrotic Myelofibrosis",
        "Myeloproliferative Disorder",
        "Myeloproliferative Disorders",
        "Myeloproliferative Disorders (MPD)",
        "Myeloproliferative Neoplasms (MPNs)",
        "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis",
        "Myeloproliferative Neoplasm With 10% Blasts or Higher",
        "Myeloproliferative Neoplasms",
        "MPN",
        "MPN (Myeloproliferative Neoplasms)",
        "MPN-associated Myelofibrosis",
        "Myeloproliferative Neoplasm, Unclassifiable",
        "Myeloproliferative Neoplasm, Not Otherwise Specified",
        "Accelerated Phase MPN",
        "Accelerated Phase Myeloproliferative Neoplasm",
        "Blast Phase MPN",
        "Blast Phase Myeloproliferative Neoplasm",
        "Thrombocythemia Myelofibrosis (PET-MF)",
        "Thrombocythemia, Essential",
        "Thrombocythemia, Hemorrhagic",
        "Agnogenic Myeloid Metaplasia",
        "Chronic Idiopathic Myelofibrosis",
        "Idiopathic Myelofibrosis",
        "MDS/MPN Crossover Syndromes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MPN Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2025-09-26",
      "completion_date": "2035-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-05-22T06:44:28.178Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07362225"
    },
    {
      "nct_id": "NCT04637009",
      "title": "A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myeloproliferative Neoplasm",
        "Myelodysplastic/Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "TAS1553",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-12-21",
      "completion_date": "2023-02-20",
      "has_results": false,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-05-22T06:44:28.178Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04637009"
    },
    {
      "nct_id": "NCT05524857",
      "title": "Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Fedratinib Oral Capsule 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Decitabine 20 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Fedratinib Oral Capsule 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph Jurcic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2022-01-28",
      "completion_date": "2024-04-09",
      "has_results": false,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-05-22T06:44:28.178Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05524857"
    }
  ]
}